|

Treg-enriched donor cell Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Dana-Farber Cancer Institute1

Indications

  • Myeloid Leukemia in Relapse (Disorder)1
  • Myeloid Leukemia, Acute1
  • Stem Cell Transplant Complications1
  • Graft vs Host Disease1
  • Myelodysplastic Syndromes1

Boston, Massachusetts1 trial

IS-free Treg HaploHCT

Dana Farber Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.